By David Woods (hmi3000@comcast.net) With healthcare in the US consuming about 16% of GNP, or around 2 trillion dollars a year, and still leaving an estimated 47 million people uninsured,…
DetailsBy Mary Gabb (mary.gabb@rxcomms.com) The UK ‘s National Institute for Health and Clinical Excellence (NICE) has recently ruled that four drugs used to treat advanced kidney cancer are not effective…
DetailsBy Ruth Whittington (ruth.whittington@rxcomms.com) Rx Communications has just returned triumphant from the 11th annual European Congress of ISPOR. ISPOR is a great place to meet old friends, find new ones,…
DetailsBy Julie Stauffer (julie.stauffer@rxcomms.com) Pharmaceutical companies produce hundreds of life-saving drugs every year. Yet each year, millions of people in developing countries die from preventable and treatable illnesses – diseases…
DetailsBy Robert Hand (robert.hand@rxcomms.com) Under the title “Setting the Pace,” the American Medical Writers Association (AMWA) held its 68th Annual Conference on October 23–25 in horse country, Louisville , Kentucky…
DetailsBy David Woods (david.woods@rxcomms.com) Drug company Eli Lilly has said that it will start disclosing the amounts of money over $500 that it pays to physicians – and other firms…
DetailsBy Mary Gabb (mary.gabb@rxcomms.com ) Since 1996, DTCA has existed only in the USA and New Zealand , but recent declarations from the European Commission (EC) suggest that the rules…
DetailsBy Mary Gabb (mary.gabb@rxcomms.com ) The publication several years ago of Selling Sickness: How the World’s Biggest Pharmaceutical Companies are Turning Us All into Patients by Ray Moynihan and Alan…
DetailsThe US Food and Drug Administration (FDA) in August proposed a new guideline asking the sponsors of clinical trials to submit annual development safety update reports (DSURs). The guideline, titled “E2F Development Safety Update Report,” is in draft form and describes the format, content, and timing of a DSUR.
DetailsBy Julie Stauffer (julie.stauffer@rxcomms.com) How quickly can you lay your hands on tomorrow’s meeting agenda, the latest batch of clinical data, or the draft report you’ve been asked to review?…
Details
